Catalyst holds firm on $300,000-plus net for Firdapse despite Bernie Sanders’ demands to justify the price

12th February 2019 Uncategorised 0

Catalyst Pharmaceuticals says it’s not bowing to pressure on pricing for rare-disease drug Firdapse—in fact, it’s quoting a $300,000 net price after payer rebates. And that’s despite a scathing letter from Sen. Bernie Sanders blasting the company for its “blatant fleecing of American taxpayers.”

More: Catalyst holds firm on 0,000-plus net for Firdapse despite Bernie Sanders’ demands to justify the price
Source: fierce